Clinical trials: Lipoprotein (a)
- Condition Lipoprotein (a)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.
- Trial name
- NCT03426033
- Testing
- ISIS 681257, Warfarin
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
Meningococcal B Disease
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
The purpose of this study is to investigate the immunogenicity, safety and tolerability of a new vaccine that might prevent meningococcal B disease. The study will be conducted in healthy toddlers aged between 12 and 24 months.
- Trial name
- NCT02534935
- Testing
- rLP2086 vaccine, Pediatric HAV vaccine
- Where
- 25 sites in Australia, Czechia and 2 more
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningitis, Meningococcal
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 μg rLP2086 vaccine in a 0, 2, 6 month schedule or control.
- Trial name
- NCT01352793
- Testing
- rLP2086 vaccine, control
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 5,715 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
- Trial name
- CLEAR Path 1 (NCT05694260)
- Testing
- Bempedoic acid
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 31 people
- Sponsor
- Esperion Therapeutics, Inc.
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
- Trial name
- NCT00028301
- Testing
- Atazanavir, Lopinavir/Ritonavir
- Where
- 97 sites in United States, Argentina and 13 more
- Sponsor
- Bristol-Myers Squibb
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to <12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein…
- Trial name
- ORION-20 (NCT06597019)
- Testing
- Inclisiran
- Where
- 66 sites in United States, Argentina and 21 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals